2023
DOI: 10.1007/s00787-023-02315-4
|View full text |Cite
|
Sign up to set email alerts
|

Case report: clinical improvements observed in first off-label metreleptin treatment of a patient with atypical anorexia nervosa

Johannes Hebebrand,
Jochen Antel,
Triinu Peters

Abstract: Off-label metreleptin treatment resulted in cognitive, emotional and behavioral improvements of patients with anorexia nervosa, who presented with hypoleptinemia. We now report a case study of a 16-year-old female patient with atypical anorexia nervosa who was treated off-label with metreleptin for 11 days. She had lost 21 kg over 6 months. Her body mass index at referral for inpatient treatment was 20 kg/m2, her serum leptin level was just within the normal range (2.4 ng/ml). Dosing resulted in prominent impr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
4
1

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 25 publications
0
3
0
Order By: Relevance
“…The hypothesis that leptin plays a substantial role in entrapment has been supported by a Mendelian randomization study linking a low leptin level to an increased risk for development of AN (Peters, Antel, et al, 2021). Further, recent case reports of off-label treatment with recombinant human leptin (metreleptin) have entailed clinical improvements and the lessening of entrapment in patients with both AN (Antel et al, 2021;Gradl-Dietsch et al, 2023;Hebebrand, Antel, von Piechowski, et al, 2023;Milos et al, 2020) and atypical AN (Hebebrand, Antel, & Peters, 2023).…”
Section: Mechanisms Underlying Prediction Of Weight Loss By Premorbid...mentioning
confidence: 99%
“…The hypothesis that leptin plays a substantial role in entrapment has been supported by a Mendelian randomization study linking a low leptin level to an increased risk for development of AN (Peters, Antel, et al, 2021). Further, recent case reports of off-label treatment with recombinant human leptin (metreleptin) have entailed clinical improvements and the lessening of entrapment in patients with both AN (Antel et al, 2021;Gradl-Dietsch et al, 2023;Hebebrand, Antel, von Piechowski, et al, 2023;Milos et al, 2020) and atypical AN (Hebebrand, Antel, & Peters, 2023).…”
Section: Mechanisms Underlying Prediction Of Weight Loss By Premorbid...mentioning
confidence: 99%
“…Additionally, further studies will be necessary to identify the molecular mechanisms behind GABAergic alterations. Recent case reports showed that short term treatment of AN patients with leptin, improved their mood and reduced hyperactivity [44, 45]. As mood and hyperlocomotion involve dopamine transmission and leptin is known to modulate the VTA, including VTA GABA neurons [46, 47] and the drive for exercise [4850], decreased leptin levels may be a causal factor in the reduced GABAergic signaling we found.…”
Section: Discussionmentioning
confidence: 55%
“…The delta of leptin concentrations between premorbid and acute stage may also be important. For instance, patients with premorbid overweight who develop AAN may well have higher mean leptin concentrations than patients with AN despite a psychopathology indistinguishable from acute AN (Hebebrand, Antel, & Peters, 2023). Entrapment in starvation was not observed in the Minnesota Starvation Experiment (Keys et al, 1950).…”
Section: How To Explain the Rapid Improvements Observed Upon Off-labe...mentioning
confidence: 94%